Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.
Solid Tumor
DRUG: CEP-9722
Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data, Up to 42 days
Pharmacokinetic parameters, Days 1 and 5 of Cycle 1 and on Day 5 of Cycle 2|Pharmacodynamics assay, Days 1, 5, and 8 of both Cycle 1 and Cycle 2|Efficacy - will be assessed by the proportion of patients who achieve tumor response during the study, A 14-day cycle and at least one 28-day cycle
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.